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Endothelial progenitor cells (EPCs) are hematopoietic 
stem cells expressing CD34, CD133, type 2 vascular 
endothelial growth factor (VEGF) receptor (VEGFR-2 or 
Flk-1), and the CXCR4 chemokine receptor [1-4]. During 
vasculogenesis, EPCs are mobilized from the bone 
marrow and they diﬀ erentiate into mature endothelial 
cells [3]. Under normal conditions, vasculogenesis is 
involved in both prenatal and postnatal tissue develop-
ment, vascular repair, and atherosclerosis [2,3].
In rheumatoid arthritis (RA), several groups have 
described defective vasculogenesis related to impaired 
EPC numbers and functions in RA [4-6]. Impaired 
vasculo genesis has been associated with increased 
cardio vascular morbidity and mortality in RA [7,8]. 
Eﬀ ective antirheumatic therapy, such as corticosteroids 
and tumor necrosis factor-alpha (TNF-α) blockers, may 
stimulate the outgrowth and function of EPCs and thus 
may restore defective vasculogenesis in arthritis [5]. In 
addition, as the induction of vasculogenesis may be 
beneﬁ cial for patients with cardiovascular disease [8], the 
stimulation of EPCs and vasculogenesis may also 
suppress premature atherosclerosis underlying RA [7].
In the previous issue of Arthritis Research & Th erapy, 
Jodon de Villeroché and colleagues [1] assessed late-
outgrowth EPCs in RA and found increased colony-
formation capacity of these cells in RA. Furthermore, 
higher or lower EPC numbers correlated with active 
disease and disease in remission, respectively. Th ese 
results seem to be somewhat controversial as a number 
of other investigators reported defective EPC function in 
RA and lower EPC numbers in active RA [5,6]. Th ere has 
been only one report by the same group, Allanore and 
colleagues [9], suggesting that circulating EPC numbers 
may be higher in RA. Nevertheless, Jodon de Villeroché 
and colleagues [1] conducted an approach that was 
signiﬁ cantly diﬀ erent from that of others. Instead of 
analyzing all EPCs, they diﬀ erentiated two EPC sub-
populations, namely EPCs of monocytic versus heman-
gio blastic origin. Th ese two EPC subsets have recently 
been described and characterized as early-outgrowth and 
late-outgrowth EPCs, respectively [1,10]. Th ere is no 
clear consensus on the accurate deﬁ nition of EPCs after 
all [10]. In their study, Jodon de Villeroché and colleagues 
[1] characterized late-outgrowth EPCs of hemangio-
blastic origin as Lin−/7-aminoactinomycin D (7AAD)−/
CD34+/CD133+/VEGFR-2+ cells and the number of these 
cells was indeed higher in RA patients compared with 
controls. In addition, the colony-forming capacity of these 
late-outgrowth EPCs was signiﬁ cantly higher in RA.
Jodon de Villeroché and colleagues [1] claim that, in all 
previous studies, EPCs also consisted of the early-
outgrowth monocyte-derived cells characterized by only 
three surface markers (CD34/CD133/VEGF-R2) [5,6]. 
According to Jodon de Villeroché and colleagues [1], the 
use of Lin and 7AAD markers may enable investigators to 
select only late-outgrowth EPCs.
Th us, while there may be a general impairment of EPC 
function and vasculogenesis in RA and low EPC numbers 
may be associated with RA activity and increased 
cardiovascular risk, late-outgrowth EPCs of solely 
heman gioblastic origin may be involved in vascular 
repair. As this EPC subset may be preferentially involved 
in the active stage of the disease, it is likely that 
hemangioblastic EPC-dependent vasculogenesis is more 
prominent in active RA associated with high-grade 
systemic inﬂ ammation and accelerated atherosclerosis. 
Abstract
Decreased number and impaired functions of 
endothelial progenitor cells (EPCs) leading to impaired 
vasculogenesis have been associated with rheumatoid 
arthritis (RA). Defective vasculogenesis has also been 
implicated in premature atherosclerosis in RA. Recently, 
early-outgrowth monocytic and late-outgrowth 
hemangioblastic EPC subsets have been characterized. 
Hemangioblastic EPCs may exert increased numbers 
in active RA and may play a role in vascular repair 
underlying RA.
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Regarding potential relevance for therapy, corticosteroids 
and anti-TNF agents may, in general, stimulate EPC 
number and function [5,11] but the possible eﬀ ects of 
these agents on the function of late-outgrowth EPCs 
need further characterization.
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